BACKGROUND: Preclinical evaluation of tuberculosis drugs is generally limited to mice. However, necrosis and hypoxia, key features of human tuberculosis lesions, are lacking in conventional mouse strains. METHODS: We used C3HeB/FeJ mice, which develop necrotic lesions in response to Mycobacterium tuberculosis infection. Positron emission tomography in live infected animals, postmortem pimonidazole immunohistochemistry, and bacterial gene expression analyses were used to assess whether tuberculosis lesions in C3HeB/FeJ are hypoxic. Efficacy of combination drug treatment, including PA-824, active against M. tuberculosis under hypoxic conditions, was also evaluated. RESULTS: Tuberculosis lesions in C3HeB/FeJ (but not BALB/c) were found to be hypoxic and associated with up-regulation of known hypoxia-associated bacterial genes (P < .001). Contrary to sustained activity reported elsewhere in BALB/c mice, moxifloxacin and pyrazinamide (MZ) combination was not bactericidal beyond 3 weeks in C3HeB/FeJ. Although PA-824 added significant activity, the novel combination of PA-824 and MZ was less effective than the standard first-line regimen in C3HeB/FeJ. CONCLUSIONS: We demonstrate that tuberculosis lesions in C3HeB/FeJ are hypoxic. Activities of some key tuberculosis drug regimens in development are represented differently in C3HeB/FeJ versus BALB/c mice. Because C3HeB/FeJ display key features of human tuberculosis, this strain warrants evaluation as a more pathologically relevant model for preclinical studies.
BACKGROUND: Preclinical evaluation of tuberculosis drugs is generally limited to mice. However, necrosis and hypoxia, key features of humantuberculosis lesions, are lacking in conventional mouse strains. METHODS: We used C3HeB/FeJ mice, which develop necrotic lesions in response to Mycobacterium tuberculosis infection. Positron emission tomography in live infected animals, postmortem pimonidazole immunohistochemistry, and bacterial gene expression analyses were used to assess whether tuberculosis lesions in C3HeB/FeJ are hypoxic. Efficacy of combination drug treatment, including PA-824, active against M. tuberculosis under hypoxic conditions, was also evaluated. RESULTS:Tuberculosis lesions in C3HeB/FeJ (but not BALB/c) were found to be hypoxic and associated with up-regulation of known hypoxia-associated bacterial genes (P < .001). Contrary to sustained activity reported elsewhere in BALB/c mice, moxifloxacin and pyrazinamide (MZ) combination was not bactericidal beyond 3 weeks in C3HeB/FeJ. Although PA-824 added significant activity, the novel combination of PA-824 and MZ was less effective than the standard first-line regimen in C3HeB/FeJ. CONCLUSIONS: We demonstrate that tuberculosis lesions in C3HeB/FeJ are hypoxic. Activities of some key tuberculosis drug regimens in development are represented differently in C3HeB/FeJ versus BALB/c mice. Because C3HeB/FeJ display key features of humantuberculosis, this strain warrants evaluation as a more pathologically relevant model for preclinical studies.
Authors: D G Niranjala Muttucumaru; Gretta Roberts; Jason Hinds; Richard A Stabler; Tanya Parish Journal: Tuberculosis (Edinb) Date: 2004 Impact factor: 3.131
Authors: Hui Pan; Bo-Shiun Yan; Mauricio Rojas; Yuriy V Shebzukhov; Hongwei Zhou; Lester Kobzik; Darren E Higgins; Mark J Daly; Barry R Bloom; Igor Kramnik Journal: Nature Date: 2005-04-07 Impact factor: 49.962
Authors: Farrokh Dehdashti; Perry W Grigsby; Mark A Mintun; Jason S Lewis; Barry A Siegel; Michael J Welch Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2012-06-04 Impact factor: 5.191
Authors: Vikram Saini; Nicole C Ammerman; Yong Seok Chang; Rokeya Tasneen; Richard E Chaisson; Sanjay Jain; Eric Nuermberger; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Alexander Mahnke; Robert J Meier; Valentin Schatz; Julian Hofmann; Kirstin Castiglione; Ulrike Schleicher; Otto S Wolfbeis; Christian Bogdan; Jonathan Jantsch Journal: J Invest Dermatol Date: 2014-02-28 Impact factor: 8.551
Authors: Si-Yang Li; Scott M Irwin; Paul J Converse; Khisi E Mdluli; Anne J Lenaerts; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2015-04-27 Impact factor: 5.191
Authors: Filipa Mota; Ravindra Jadhav; Camilo A Ruiz-Bedoya; Alvaro A Ordonez; Mariah H Klunk; Joel S Freundlich; Sanjay K Jain Journal: ACS Infect Dis Date: 2020-04-09 Impact factor: 5.084
Authors: Smriti Mehra; Xavier Alvarez; Peter J Didier; Lara A Doyle; James L Blanchard; Andrew A Lackner; Deepak Kaushal Journal: J Infect Dis Date: 2012-12-18 Impact factor: 5.226